Nimotuzumab in Adults With Glioblastoma Multiforma
Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV
Sponsor: Dep. of Neurosurgery and Policlinic, University Hospital, Dresden, Germany
This PHASE3 trial investigates Adults With Glioblastoma Multiforma and is currently completed. Dep. of Neurosurgery and Policlinic, University Hospital, Dresden, Germany leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2018 [monthly]
Completed PHASE3
First recorded
Aug 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dep. of Neurosurgery and Policlinic, University Hospital, Dresden, Germany
- Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany
- Heinrich-Heine University, Duesseldorf
- Johann Wolfgang Goethe University Hospital
- Neurological Clinic, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany
- Oncoscience AG
- University of Bonn
- University of Giessen
- University of Kiel
- Universität Tübingen
- Universitätsklinikum Hamburg-Eppendorf
For direct contact, visit the study record on ClinicalTrials.gov .